Clinical Trial Detail

NCT ID NCT02143414
Title Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

B-cell acute lymphoblastic leukemia

Therapies

Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate

Dasatinib + Prednisone

Blinatumomab + Dasatinib

Blinatumomab

Age Groups: senior

No variant requirements are available.